CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.5M, lower than 95% of all stocks globally
- PositionOperating margin is -4974.3%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.81BUSDvs all stocks (USD)
Revenue (TTM)
7.50MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6270xvs all stocks
52-Week Change
54.97%vs all stocks
Market Capitalization
5.81BUSDvs all stocks (USD)
Enterprise Value
5.07BUSDvs all stocks (USD)
Forward P/E
-12.73xvs Biotechnology peers
Price to Book (MRQ)
4.82xvs Biotechnology peers
Enterprise to Revenue
676.41xvs Biotechnology peers
Enterprise to EBITDA
-11.55xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4974.27%vs Biotechnology peers
Return on Assets (TTM)
-28.02%vs Biotechnology peers
Return on Equity (TTM)
-43.62%vs Biotechnology peers
Revenue (TTM)
7.50MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0946USDUpdated Aug 28, 2026Gross Profit (TTM)
-352.48MUSDvs all stocks (USD)
EBITDA (TTM)
-439.19MUSDvs all stocks (USD)
Net Income (TTM)
-409.20MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-337.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-203.55MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
7.50MUSDFY2025 · Dec 31, 2025Operating Income
-373.07MUSDvs all stocks (USD)
Pre-tax Income
-344.89MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.02MUSDFY2025 · Dec 31, 2025Net Income
-345.91MUSDFY2025 · Dec 31, 2025EBIT
-373.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-371.88MUSDFY2025 · Dec 31, 2025Research & Development
300.94MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
79.63MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
26.83MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.36USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.36USDFY2025 · Dec 31, 2025Basic Shares Outstanding
79.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-345.91MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-289.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-290.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
199.16MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-345.91MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.54MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-3.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
53.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.31MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
104.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.90MUSDFY2025 · Dec 31, 2025Capital Expenditures
-799.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-355.66MUSDFY2025 · Dec 31, 2025Sale of Investments
574.45MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
218.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
112.15MUSDFY2025 · Dec 31, 2025Shares Outstanding
96.62MSharesUpdated Aug 28, 2026Float Shares
90.95MSharesUpdated Aug 28, 2026Shares Short
5.67MSharesUpdated Aug 28, 2026Short Ratio
7.95daysvs all stocks
Short % of Shares Outstanding
5.86%vs all stocks
% Held by Insiders
0.11%vs all stocks
% Held by Institutions
107.62%vs all stocks
Total Cash (MRQ)
930.69MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.61USDUpdated Aug 28, 2026Total Debt (MRQ)
6.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0052xvs Biotechnology peers
Current Ratio (MRQ)
21.02xvs Biotechnology peers
Book Value per Share (MRQ)
12.84USDUpdated Aug 28, 2026Total Assets
633.16MUSDvs all stocks (USD)
Total Current Assets
560.65MUSDFY2025 · Dec 31, 2025Total Liabilities
51.40MUSDFY2025 · Dec 31, 2025Total Non-current Assets
72.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
41.79MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
199.16MUSDFY2025 · Dec 31, 2025Other Short-term Investments
349.72MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.37MUSDFY2025 · Dec 31, 2025Accounts Payable
3.88MUSDFY2025 · Dec 31, 2025Short-term Debt
1.53MUSDFY2025 · Dec 31, 2025Long-term Debt
6.41MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.20MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.60BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.25BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
581.76MUSDvs all stocks (USD)
52-Week Low
35.60USDUpdated Aug 28, 202652-Week High
72.66USDUpdated Aug 28, 202652-Week Change
54.97%vs all stocks
Beta
0.6270xvs all stocks
50-Day MA
62.89USDUpdated Aug 28, 2026200-Day MA
52.18USDUpdated Aug 28, 2026Avg 10-Day Volume
742.57KSharesUpdated Aug 28, 2026Avg 30-Day Volume
676.80KSharesUpdated Aug 28, 2026Diluted EPS (TTM)
-4.74USDUpdated Aug 28, 2026Other Income / Expense
1.35MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -4974.3%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -49.74Industry median: -0.24Industry P5: -33.54Peers compared: 194
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.5M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,500,000Global P5: 32,166,921.735
Market cap is $5.81B, above the global median of $1.18BNotable
Market cap (USD): 5,809,457,515Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Twist Bioscience Corporation
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC